Peer Review, Workforce

New CEOs at Axovant, Destiny and Organovo mark a busy week for the biotech jobs scene

Peer Review is the weekly biopharma jobs report from Endpoints News.

Neil Bodick, Flexion

→ Musculoskeletal company Flexion Therapeutics $FLXN said co-founder Neil Bodick will transition to CSO from CMO. Yamo Deniz becomes CMO. Deniz was VP and global head of medical for rare diseases at the Genzyme unit of Sanofi.

→ Rare diseases play PTC Therapeutics $PTCT said CFO Shane Kovacs will leave the company in mid-May. PTC is seeking a replacement.

→ Cell therapy concern Vericel $VCEL named Michael Halpin SVP of quality and regulatory affairs. He was VP and North American region regulatory head at Genzyme.

→ Hemophilia company Bioverativ $BIVV named Tim Harris EVP of R&D. He was a partner at SV Life Sciences.

Michael Gutch, Entasis

→ Anti-infective firm Entasis Therapeutics named Mike Gutch CFO and CBO. He was executive director of corporate development at AstraZeneca.

Lorianne Masuoka, Marinus

→ Lorianne Masuoka joins Marinus Pharmaceuticals as their new CMO. She’s a neurologist who held chief medical roles at InVivo, Cubist, and Nektar previously.

→ Taylor Crouch is replacing Keith Murphy as CEO of San Diego-based Organovo $ONVO, a developer of human tissue models. Crouch was the CEO of eStudySite, and earlier in his career was senior vice president of marketing and sales at Parexel.

→ Oxford’s e-Therapeutics appointed Raymond Barlow as CEO. Barlow was previously executive director of corporate development at Amgen.

→ Destiny Pharma, an anti-microbial biotech, named Neil Clark as CEO. Bill Love, the previous CEO and scientific founder, is now the CSO.

→ David Hung is the new CEO of Axovant $AXON. He comes by way of Medivation, where as co-founder and CEO he led the company to a $14.3 billion acquisition by Pfizer.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017